Clinical Trial Update: Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of pucotenlimab and lenvatinib as neoadjuvant therapy for non-clear cell renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• Pucotenlimab

Snippet

Sponsor: Sun Yat-sen University | Conditions: Renal Cell Carcinoma | Phase 2 | Status: UNKNOWN